Redcare Pharmacy aims for higher 2024 sales after positive annual core earnings
05/03/2024 06:32
March 5 (Reuters) - Redcare Pharmacy RDC.DE on Tuesday
forecast higher sales for 2024 after the online pharmacy
operator posted upbeat adjusted annual core earnings, supported
by a growing number of prescription sales.
The Netherlands-based group said its adjusted earnings
before interests, taxes, depreciation and amortization (EBITDA)
for the year ended Dec. 31 came in at 53.5 million euros ($58.05
million), from a loss of 8 million euros in the year-ago period.
The online pharmacy operator recorded 2023 annual sales
growth of 54.6% in its core DACH market, which comprises
Austria, Germany, and Switzerland.
Redcare Pharmacy said it aims to increase its sales by
30%-40% this year.
Swiss peer DocMorris DOCM.S said in January it aimed for
profitability on adjusted EBITDA for 2024, excluding
e-prescriptions, after it delayed this objective in 2023.
($1 = 0.9217 euros)
(Reporting by Tristan Veyet and Paolo Laudani in Gdansk;
Editing by Sherry Jacob-Phillips)
((Tristan.Chabba@thomsonreuters.com;))